attenuates effects of cyclosporine A on tight junctions and apoptosis in cultured cortical collecting duct principal cells. Am
STATINS, as inhibitors of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase used to reduce cholesterol synthesis, have been administrated to treat the dyslipidemia that commonly occurs in organ transplant recipients (38) . This dyslipidemia may be due to the use of immunosuppressant drugs such as cyclosporine A (CsA) (34) . However, there is an ongoing debate as to whether statins can be safely used for these patients to reduce cholesterol. Some clinical case analyses have indicated that statins can induce rhabdomyolysis, in which skeletal muscle breaks down and leads to renal injury in transplant recipients on CsA treatment (1, 20) , which implies that a reduced dosage of statins should be used for patients receiving CsA treatment (3) . In contrast, there are other data showing that statins are beneficial in outcomes of renal transplant recipients receiving CsA treatment (15, 22) . When given in low or modest dosages, statins are quite safe and effective for treatment of hypercholesterolemia in organ transplant recipients (2, 8, 19, 42, 47) . In a rat model of kidney transplantation, pravastatin significantly reduced renal interstitial inflammation and fibrosis (21) . However, there are few in vitro data showing the molecular mechanism by which statins can reverse side effects of CsA at the cellular level. Our recent in vitro studies have shown that CsA elevates levels of cholesterol in distal nephron cells (45) , probably through inhibition of ATP-binding cassette transporter A1 (ABCA1), which is responsible for cholesterol outward transport (46) . We assume that locally elevated cholesterol in distal nephron cells may be responsible for some of the side effects of CsA. As HMG-CoA reductase inhibitors, statins might prevent side effects of CsA by reducing cholesterol levels in renal tubular cells.
One side effect of CsA on renal tubular cells is to increase transepithelial resistance, which reflects, at least in part, paracellular permeability (16, 27) . Paracellular permeability is mainly controlled by tight junctions, specialized membrane and protein complexes formed between cells. Since tight junctions are raft-like (cholesterol-rich) membrane microdomains (30) , CsA may modulate tight junctions and reduce paracellular permeability by elevating levels of cholesterol or tight junction proteins. The possible involvement of cholesterol in cell membranes or intracellular pools encouraged us to hypothesize that lovastatin may attenuate CsA-induced reduction of paracellular permeability. Another side effect of CsA is to cause kidney injury. It has long been known that CsA induces apoptosis of proximal tubule cells (9, 33) . A recent study (40) has shown that CsA also induces apoptosis of inner medullary collecting duct cells by elevating osmolality. However, it remains unclear whether CsA can induce apoptosis of cortical collecting duct (CCD) cells. In a rat model, rosuvastatin attenuated CsA-induced inflammation, apoptosis, and fibrosis in the kidney (29) . Since CsA-induced renal tubular injury is associated with increased levels of cholesterol ester (48) , it is very likely that statins attenuate CsA-induced kidney injury by reducing cholesterol levels in the cell. However, recent studies (7, 10) have suggested that high-potency statins can increase the risk of acute kidney injury. This is not surprising because cholesterol not only maintains normal cell membrane integrity but also allows cell to gain cytoresistance (48) . Therefore, we hypothesized that CsA and statins might counteract in the regulation of cell mortality by modulating cellular cholesterol levels.
Here, we report that lovastatin attenuates CsA-decreased paracellular permeability and CsA-induced apoptosis in cultured CCD cells and that, conversely, CsA attenuates lovastatin-induced apoptosis. Therefore, the results of the present study suggest that statins may benefit patients receiving CsA treatment after organ transplantation and that CsA may be used to treat statin-induced kidney injury.
MATERIALS AND METHODS
Cell culture. A mouse CCD principal cell line (mpkCCDc14 cells) (5) was used in the present study. Cells were cultured on Transwell inserts with permeable polyester membranes, as we have previously reported (12) . Briefly, mpkCCD c14 cells were incubated in a 1:1 mix of DMEM-F-12 medium (Invitrogen, Carlsbad, CA) supplemented with 50 nM dexamethasone, 1 nM triiodothyronine, 20 mM HEPES, 2 mM L-glutamine, 0.1% penicillin-streptomycin, and 2% heat-inactivated FBS. Cells were maintained at 37°C with 5% CO 2 in air for 2 wk until they formed a confluent monolayer and became fully polarized.
Chemicals and solutions. The majority of chemicals were obtained from Sigma Chemical. The NaCl bath solution for all experiments contained (in mM) 145 NaCl, 5 KCl, 1 CaCl 2, 1 MgCl2, and 10 HEPES (pH was adjusted to 7.4 with NaOH). All concentrations throughout this article represent final concentrations.
Measurement of transepithelial resistance. After culture on the polyester membrane of Transwell inserts for 2 wk, mpkCCD c14 cells were fully polarized and formed cell monolayers. The resistance across the cell monolayer was measured with electrodes connected to a volt-ohm meter, the EVOM (World Precision Instruments, Sarasota, FL), as we have previously reported (26) . Resistance was corrected for the surface area of the polyester membrane (expressed in ⍀·cm 2 ). Scanning ion conductance microscopy. Scanning ion conductance microscopy (SICM) experiments were performed as previously described (11) . SICM images of the apical membrane of mpkCCD c14 cells were obtained with an XE-Bio system (Park Systems, Suwon, Korea) in an adaptive approach-retract-scan mode, as we have previously described (23) . Live mpkCCD c14 cells on permeable polyester membranes (Transwell) were mounted on the stage of an inverted Nikon Eclipse Ti microscope (Nikon, Tokyo, Japan). The morphology of the cell surface at nanometer resolution was scanned with the SICM probe, a glass pipette, and by an XY flat scanner attached to the microscopy stage and a Z scanner attached to the SICM head. The glass pipette was fabricated from borosilicate capillaries (inner diameter: 0.6 mm and outer diameter: 1.0 mm) using a CO 2-laser-based micropipette puller (P-2000, Sutter Instruments, Novato, CA). The inner and outer diameters of the pipette tip were ϳ100 and 200 nm, respectively. Before the experiment, cells were thoroughly washed with NaCl bath solution and transferred into the SICM live cell chamber on an inverted microscopic stage. The glass pipette was filled with electrolyte, NaCl bath solution. The current between the pipette and the cell membrane was set at a constant value by a feedback circuit to keep the pipette tip at a proximal, fixed distance from the cell surface. Images of the apical membrane surface were then made by scanning the cell surface with the pipette. Three-dimensional images were reconstructed, and the heights of protrusions from the apical membrane of mpkCCD c14 cells were calculated with the software attached to the XE-Bio system.
Confocal microscopy. Confocal microscopy experiments were performed as previously described (26) . Briefly, to detect levels of zonula occludens (ZO)-1 in mpkCCD c14 cells, cells were fixed with 4% paraformaldehyde for 10 min, washed twice, permeabilized with 0.1% Triton X-100 in NaCl bath solution for 15 min, and then washed twice. Cells were incubated with rabbit anti-ZO-1 antibody (Invitrogen) for 1 h, washed twice, and incubated with a secondary antibody (Alexa fluor 594, goat anti-rabbit IgG, 5 g/ml) at room temperature for 1 h. To detect levels of cholesterol, live cells were stained with a membrane-permeable, cholesterol-binding, fluorescent probe, filipin. Before the confocal miscroscopy experiments, cells were washed twice with NaCl bath solution. Immediately after each experimental manipulation, the polyester membrane that supported the mpkCCD c14 cell monolayer was quickly excised and mounted on a glass slide with either a drop of mounting solution for the ZO-1 labeling or a drop of NaCl bath solution to keep the cells alive for the cholesterol labeling. XY or XZ scanning of mpkCCD c14 cells was accomplished with an Olympus FV-1000 confocal microscopy within 3 days for the ZO-1 labeling using fixed cells or within 10 min for the cholesterol labeling using live cells. XY optical sections were performed to provide a flat view of the cells near the apical membrane. XZ optical sections were also performed to provide a lateral view of the cells. In each set of experiments, images were taken using the same parameter settings.
To evaluate apoptosis, mpkCCD c14 cells were stained with both FITC-conjugated annexin V (AV) and propidium iodide (PI), as we have previously described (24) . The cell membrane of apoptotic cells was stained with AV because phosphatidylserine, a lipid that has a high binding affinity to AV, is externalized in apoptotic cells. The nuclei of apoptotic cells were stained with PI because the nuclear membrane of apoptotic cells becomes permeable to PI. AV was excited with a 488-nm laser and visualized through a 515-nm emission filter (shown in green). PI was excited with a 488-nm laser and visualized through a 590-nm emission filter (shown in red). To detect levels of intracellular ROS, mpkCCD c14 cells were incubated with 25 M 2=,7=-dichlorodihydrofluorescein diacetate a membrane-permeable, ROS-sensitive, fluorescent probe for 15 min. Confocal microscopy XY scanning of mpkCCD c14 cells was accomplished within 5-15 min. In each set of experiments, images were taken using the same parameter settings.
Western blot experiments. To detect levels of ZO-1 and p47 phox in mpkCCDc14 cells, cell lysates (100 g) were loaded and electrophoresed on 10% SDS-PAGE gels for 60 -90 min. Gels were blotted onto polyvinylidene fluoride membranes for 1 h at 90 V. After a 1-h block with 5% BSA-PBS-Tween buffer, polyvinylidene fluoride membranes were incubated with primary antibodies (1:1,000 dilution) of either rabbit anti-ZO-1 antibody (lot no. 8831P1, Sigma) or goat anti-NCF1 (p47 phox ) antibody (lot no. GR84191-5, Abcam), respectively, overnight at 4°C and then respectively incubated with the appropriate horseradish peroxidase-conjugated secondary antibodies (1:5,000 dilution, GE Healthcare) for 1 h after four vigorous washes. Finally, blots were visualized with chemiluminescence using an ECL Plus Western Blotting Detection System (GE Healthcare).
Statistical analysis. ANOVA for multiple comparisons was used for comparison among multiple groups of data. The Holm-Sidak method was used for the posttest of multiple comparisons. Data are shown as means Ϯ SD. P values of Ͻ0.05 were considered statistically significant.
RESULTS

Lovastatin abolishes both CsA elevation of transepithelial resistance and CsA modification of cell topographic structure.
Since one side effect of CsA is to reduce the paracellular permeability of renal tubular cells (16, 27) , we first examined the effect of CsA on transepithelial resistance across monolayers of a renal principal cell line, mpkCCD c14 cells. As shown in Fig (n ϭ 12, P Ͻ 0.001). Since our previous study (45) showed that CsA elevates intracellular cholesterol, we hypothesized that lovastatin might antagonize the effects of CsA. Indeed, resistance remained at control levels (3,776 Ϯ 250 ⍀·cm 2 , n ϭ 12, P Ͼ 0.05), when cells were cotreated for 24 h with both 1 M CsA and 25 M lovastatin. These data suggest that lovastatin antagonizes the effects of CsA on transepithelial resistance.
Since paracellular permeability is generally tightly controlled by tight junctions, we thought that CsA might induce cell membrane topographic changes near tight junctions. SICM allowed us to detect, at nanometer resolution, the difference in height of the cell surface. Therefore, we used SICM to determine whether CsA and lovastatin could modulate apical topographic structures of mpkCCD c14 cells. We found that the apical membrane of mpkCCD c14 cells contained significantly elevated protrusions near tight junctions (Fig. 2, A and B) . These data suggest that lovastatin reverses CsA-induced topographic changes near tight junctions.
CsA increases, but lovastatin decreases, ZO-1 expression via a cholesterol-dependent mechanism. The topographic changes near tight junctions implied some remodeling of tight junctions. A previous study (4) has shown that overexpression of ZO-1 increases paracellular permeability. However, upregulation of endogenous ZO-1 expression decreased paracellular permeability, as shown by increased transepithelial resistance (18) . Therefore, we determined how CsA would affect levels of ZO-1 in mpkCCD c14 cells. Confocal microscopy data showed that treatment of cells with 1 M CsA for 24 h significantly increased the amount of ZO-1 in tight junctions (Fig. 3, A and B) . In contrast, treatment of cells with 25 M lovastatin for 24 h to reduce cholesterol synthesis significantly decreased the amount of ZO-1. However, ZO-1 remained approximately unchanged when cells were treated with both 1 M CsA and 25 M lovastatin together for 24 h. To confirm the results from confocal microscopy experiments, Western blot experiments were performed using control (untreated) cells and cells treated for 24 h with 1 M CsA, 25 M lovastatin, 1 M CsA plus 25 M lovastatin, or 30 g/ml cholesterol. CsA increased, and lovastatin decreased, ZO-1 expression in mpkCCD c14 cells (Fig. 3C) . The effect of CsA on ZO-1 expression was abolished by lovastatin and mimicked by cholesterol, indicating that the contrary effects of CsA and lovastatin are probably through a cholesterol-dependent mechanism. We also found that treatment of cells with 30 g/ml cholesterol significantly increased transepithelial resistance from 3,920 Ϯ 123 to 5,538 Ϯ 328 ⍀·cm 2 (n ϭ 11, P Ͻ 0.001; Fig. 3D ), indicating that cholesterol mediates the CsA-induced elevation of transepithelial resistance. A: representative images either from XY optical sections performed near the apical membrane (top) or from XZ optical sections (bottom) when cells were under control conditions or were treated with CsA, lovastatin, or lovastatin plus CsA. All images were taken using the same parameters, including the detector gain. To avoid saturating the fluorescence in the area of tight junctions, the detector gain in all experiments was set at a low level; at this level, the cholesterol in other parts of the cell membrane was not visible. B: summary plots of fluorescence intensity reflecting the levels of cholesterol under each condition as shown in A. In each group, n ϭ 7.
CsA increases, but lovastatin decreases, levels of cholesterol in or near tight junctions.
Since tight junctions are considered to be raft-like (cholesterol-rich) membrane microdomains (30), we also used confocal microscopy to determine the levels of cholesterol in tight junctions by staining cells with a fluorescent, cholesterol-binding compound, filipin. In parallel with the effects on the levels of ZO-1, confocal microscopy showed that treatment of cells with 1 M CsA for 24 h significantly increased the levels of cholesterol in both tight junctions and the apical membrane of mpkCCD c14 cells (Fig. 4, A and B) . In contrast, but as might be expected, treatment of cells with 25 M lovastatin for 24 h significantly decreased the levels of cholesterol. Cholesterol changed little when cells were treated with both 1 M CsA and 25 M lovastatin together for 24 h. These data, together with the data shown in Fig. 3C , suggest that lovastatin antagonizes the effect of CsA on the levels of ZO-1, probably through modification of the levels of cholesterol in the tight junction complex.
A high concentration of CsA induces apoptosis, which is attenuated by lovastatin. The above experiments showed that CsA at 1 M caused defective paracellular transport within 24 h. The concentration of CsA can reach 2,629 ng/ml (2.2 M) in the urine of healthy individuals after a single dose (17) . We hypothesized that CsA at a concentration higher than 1 M and for treatment longer than 24 h may induce apoptosis. Therefore, mpkCCD c14 cells were stained with AV-FITC and PI. Sustained treatment of mpkCCD c14 cells with lovastatin induces apoptosis, which is attenuated by CsA. A recent study (10) has indicated that the use of high-potency statins is associated with an increased rate of acute kidney injury. Since the concentration of lovastatin we used in the above experiments to acutely reduce cholesterol synthesis in cells was already relatively high, we hypothesized that sustained treatment of mpkCCD c14 cells with the same concentration of lovastatin might induce apoptosis. Confocal microscopy experiments were performed in mpkCCD c14 cells either under control conditions or treated with 25 M lovastatin for 24 h, 48 h, or 72 h. As shown in Fig. 6 , A and B, treatment of cells for 24 and 48 h did not significantly affect cell mortality. In contrast, treatment of cells for 72 h caused significant apoptosis. Interestingly, the apoptosis induced by sustained treatment with lovastatin was significantly attenuated by cotreatment of cells with 1 M CsA. These data suggest that CsA can antagonize lovastatin-induced apoptosis of cultured mpkCCD c14 cells. (Fig. 7, A and C) . In parallel, Western blot data showed that treatment of cells for 24 h with 5 M CsA, but not 1 M CsA, significantly elevated the expression of p47 phox , a regulatory subunit of NADPH oxidase (Fig. 8) . Although treatment of cells with 25 M lovastatin for 72 h caused apoptosis, as shown in Fig. 6 , the treatment did not elevate intracellular ROS (Fig. 7, B and D) . These data suggest that a high concentration of CsA elevates ROS by activation of NADPH oxidase, probably via stimulation of p47 phox expression.
DISCUSSION
Immunosuppresive drugs such as CsA and tacrolimus are extensively used for reducing allograft rejections, and they suppresses immune responses via inhibition of calcineurin, a protein phosphatase (32). However, both CsA and tacrolimus have side effects such as inducing nephrotoxicity (28) and causing hypertension (14) . Although CsA-and tacrolimusinduced nephrotoxicity is severe, so far, there are no other drugs that can completely replace their important role in treating the rejection of organ transplants. Therefore, reducing their side effects becomes very critical for improving the management of allograft rejections. A recent study (13) has shown that tacrolimus causes hypertension by stimulating the renal NaCl cotransporter in the distal convoluted tubule via a calcinerin-dependent pathway. Since CsA induces greater hypertension than tacrolimus (36), besides via inhibition of calcineurin, CsA may cause hypertension also via another mechanism. Indeed, CsA, but not tacrolimus, also inhibits the ABCA1 transporter (25) , which is responsible for Cho transport out of the cells (46) . Our recent study (45) suggested that CsA causes hypertension by also stimulating the epithelial Na ϩ channel in distal nephron cells via ABCA1-dependent elevation of cholesterol. This study indicates that modulation of cholesterol levels in cell membranes or membrane pools may serve as a signaling pathway to mediate side effects of CsA. Indeed, the results of the present study showed that CsAinduced elevation of both ZO-1 and cholesterol levels in or near tight junctions appears to account for CsA-reduced paracellular permeability.
Using SICM nanotechnology, for the first time, we showed that CsA and lovastatin have contrary effects on topographic structures of the specialized membranes between CCD cells where tight junctions are located. Under basal conditions, the membranes between two cells seem to integrate into one membrane, which forms protrusions on the top of tight junctions; CsA enhances the protrusions, whereas lovastatin eliminates the protrusions. These topographic changes induced by CsA and lovastatin dramatically parallel the changes in the levels of ZO-1 and cholesterol. The concentration of CsA we used (1 M) to induce these changes is less than the maximum CsA concentration (2,629 ng/ml ϭ 2.2 M) found in the urine of healthy individuals after a single dose (17) . A recent study (6) has shown that pharmacological concentrations of CsA (10 -40 g/ml ϭ 8 -33 M) decrease tight junction proteins, including ZO-1, in proximal tubular cells. Since CsA also causes apoptosis at these concentrations (6), the decreases in tight junction protein levels caused by pharmacological concentrations of CsA may be due to nonspecific protein degradation commonly observed under apoptotic conditions. Our finding that CsA increases, but lovastatin decreases, the levels of cholesterol in tight junctions is significant because these results suggest that cholesterol can be locally synthesized in renal epithelial cells and that its levels in tight junctions can also be locally controlled. Our recent study (45) has shown that CsA promotes exogenous cholesterol accumulation in distal nephron cells, indicating that CsA elevates levels of cholesterol by reducing cholesterol loss from the cell. Since treatment of cells either with lovastatin to inhibit cholesterol synthesis or with exogenous cholesterol can antagonize or mimic, respectively, the effect of CsA on ZO-1 expression, we argue that CsA may enhance ZO-1 expression by elevating cholesterol in the cells. We propose that statins may improve the CsAinduced defects in paracellular transport. In addition to inducing defective paracellular transport, a high concentration of CsA also causes apoptosis in renal epithelial LLC-PK1 cells (9) . The present study showed that CsA at 5 M can cause apoptosis of cultured mpkCCD c14 cells. Since the CsA concentration in the urine of healthy individuals even after a single dose can reach 2.2 M (17), we argue that the urinary CsA levels in patients on CsA therapy with reduced kidney function may be even higher than the concentrations we used in the present study. Consistent with the evidence obtained in mesangial cells (31) , we showed that CsA also causes oxidative stress in mpkCCD c14 cells. CsA elevates intracellular ROS by activating NADPH oxidase and promoting the expression of the regulatory subunit of NADPH oxidase, p47
phox . As an inhibitor of the cholesterol transporter ABCA1, CsA can cause the accumulation of cholesterol in distal nephron cells (45) . It has been reported that the assembly and activity of NADPH oxidase are dependent on cholesterolrich membrane microdomains, lipid rafts (37, 44) . Therefore, we argue that the CsA-induced accumulation of cholesterol in mpkCCD c14 cells may be responsible for the CsA-induced elevation of intracellular ROS by activation of NADPH oxidase. Consistent with a previous report (43), we showed that CsA at 1 M did not affect p47 phox expression. However, our new finding is that CsA at 5 M significantly stimulated p47 phox expression, elevated intracellular ROS, and induced apoptosis of mpkCCDc14 cells. Since urinary CsA levels almost can reach the concentration we used in the in vitro experiments, CsA may be harmful to the distal tubule in patients on high doses of CsA. More importantly, CsA-induced apoptosis is attenuated by lovastatin. These data provide important information for further determining whether lovastatin can be used to improve CsA-induced nephrotoxicity.
It is well documented that statins, when given in low or modest dosages, are quite safe and effective for the treatment of hypercholesterolemia in organ transplant recipients (2, 8, 19, 42, 47) . Even at a high dose (80 mg), if it is a single dose, atorvastatin can improve acute kidney injury (35) . The present in vitro study supports previous findings by showing that treatment of mpkCCD c14 cells with lovastatin even at 25 M did not induce significant apoptosis within 48 h. However, recent studies (7, 10) have indicated that high-potency statins can increase the risk of acute kidney injury. Indeed, we showed that sustained treatment of mpkCCD c14 cells with lovastatin caused significant apoptosis. Since such a treatment did not elevate intracellular ROS, the mechanism by which lovastatin induces apoptosis remains to be further determined. Our exciting finding is that lovastatin-induced apoptosis can be attenuated by 1 M CsA. At this concentration, CsA does not induce apoptosis but only reduces paracellular permeability, which is abolished by lovastatin. These results provide useful information for further determining whether CsA can be used to improve acute kidney injury induced by high-potency statins. Although the plasma concentrations of lovastatin in human subjects receiving lovastatin are usually Ͻ20 ng/ml (50 nM) (39), a recent study (41) has suggested that simvastatin can be safely used for chemotherapy at a relatively high dose of 15 mg·kg Ϫ1 ·day
Ϫ1
. Assuming the average blood volume is 5,000 ml, this high dose would result in a calculated plasma concentration of simvastatin is ϳ7 M. Therefore, the pharmacological concentrations of lovastatin we used in the present in vitro study provide useful information to control statin nephrotoxicity and to guide the use of statins in cancer chemotherapy.
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